USA - NASDAQ:AVGR - US0537348775 - Common Stock
The current stock price of AVGR is 0.474 USD. In the past month the price decreased by -19.65%. In the past year, price decreased by -84.07%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 219.11B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.92 | 206.56B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.21 | 149.52B | ||
| SYK | STRYKER CORP | 26.96 | 135.73B | ||
| IDXX | IDEXX LABORATORIES INC | 56.27 | 56.77B | ||
| BDX | BECTON DICKINSON AND CO | 12.6 | 52.06B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.72 | 49.36B | ||
| RMD | RESMED INC | 25.26 | 36.50B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.01 | 33.55B | ||
| PODD | INSULET CORP | 70.1 | 22.55B | ||
| DXCM | DEXCOM INC | 29.48 | 21.51B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.97 | 17.58B |
Avinger, Inc. is a commercial-stage medical device company, which engages in the designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease. The company is headquartered in Redwood City, California and currently employs 68 full-time employees. The company went IPO on 2015-01-30. The firm designs, manufactures, and sells real-time, image-guided, minimally invasive catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). Its Lumivascular platform includes the Lightbox real-time imaging console, the Ocelot and Tigereye family of catheters, which are image-guided catheters designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO), and the Pantheris family of catheters, its image-guided atherectomy family of catheters designed to allow physicians to remove arterial plaque in PAD patients. Its Pantheris is a single-use product and provides physicians with the ability to see a cross-sectional view of the peripheral artery to guide the removal of blockages throughout the procedure. The company has also developed a line extension of its Pantheris image-guided atherectomy platform, Pantheris Small Vessel (SV).
Avinger Inc
400 Chesapeake Dr
Redwood City CALIFORNIA 94063 US
CEO: Jeffrey M. Soinski
Employees: 71
Phone: 16503632400
Avinger, Inc. is a commercial-stage medical device company, which engages in the designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease. The company is headquartered in Redwood City, California and currently employs 68 full-time employees. The company went IPO on 2015-01-30. The firm designs, manufactures, and sells real-time, image-guided, minimally invasive catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). Its Lumivascular platform includes the Lightbox real-time imaging console, the Ocelot and Tigereye family of catheters, which are image-guided catheters designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO), and the Pantheris family of catheters, its image-guided atherectomy family of catheters designed to allow physicians to remove arterial plaque in PAD patients. Its Pantheris is a single-use product and provides physicians with the ability to see a cross-sectional view of the peripheral artery to guide the removal of blockages throughout the procedure. The company has also developed a line extension of its Pantheris image-guided atherectomy platform, Pantheris Small Vessel (SV).
The current stock price of AVGR is 0.474 USD. The price decreased by -20.74% in the last trading session.
AVGR does not pay a dividend.
AVGR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
AVGR stock is listed on the Nasdaq exchange.
Avinger Inc (AVGR) has a market capitalization of 1.57M USD. This makes AVGR a Nano Cap stock.
You can find the ownership structure of Avinger Inc (AVGR) on the Ownership tab.
ChartMill assigns a fundamental rating of 2 / 10 to AVGR. While AVGR seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months AVGR reported a non-GAAP Earnings per Share(EPS) of -11.03. The EPS increased by 66.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -127.59% | ||
| ROE | -447.82% | ||
| Debt/Equity | 0 |
7 analysts have analysed AVGR and the average price target is 5.1 USD. This implies a price increase of 975.95% is expected in the next year compared to the current price of 0.474.
For the next year, analysts expect an EPS growth of -30.64% and a revenue growth -12.9% for AVGR